Skip to main content
Premium Trial:

Request an Annual Quote

MedGenome Acquires Lifecode Health

NEW YORK (GenomeWeb) – MedGenome said today that it has acquired Lifecode Health, a Foster City, California-based cancer molecular diagnostics company.

MedGenome, a Bangalore, India-based genomics diagnostics and research firm, said that the acquisition will give it access to Lifecode's 13,000-square-foot, CLIA-certified and CAP-accredited laboratory and enable it to expand its genomics services to biotechnology and pharmaceutical companies in the US.

Lifecode was originally launched in 2013 as Silicon Valley Biosystems. Last year, the company changed its name and also completed a $20.5 million Series A financing round. The company offers an NGS-based pan-cancer test and in 2013 struck up a collaboration with the Mayo Clinic to develop a clinical sequencing pipeline.

In a statement, MedGenome's CEO Sam Santhosh said that US biotech and pharmaceutical companies are already using its research services in areas such as cancer and immunotherapies, metabolic diseases, Parkinson's disease, kidney, liver, and ophthalmological diseases, diabetes, deafness, and aging, but that the acquisition would "allow us to grow our customer base even more aggressively in the US."

MedGenome said it has retained some "key employees" of Lifecode. Financial details and other terms were not disclosed.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.